{"url_path":"/sec/cik-0001697884/10-k/2026/item-9c","section_key":"item-9c","section_title":"Item 9C Disclosures Regarding Foreign Jurisdictions that Prevent Inspections.**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","accession_number":"0001640334-26-001082","cik":"0001697884","ticker":null,"issuer_name":"VITASPRING BIOMEDICAL CO. LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","primary_entity_key":"0001697884","primary_entity_name":"VITASPRING BIOMEDICAL CO. LTD."},"word_count":103,"has_tables":true,"body_markdown":"**Item 9C. Disclosures Regarding Foreign Jurisdictions that Prevent Inspections.**\n\n \n\nThe Public Company Accounting Oversight Board (“PCAOB”) is currently able to inspect or investigate completely our independent registered public accounting firm, as the firm is located in a jurisdiction that permits such inspections.\n\n \n\nWe are not currently identified by the Securities and Exchange Commission as a “Commission-Identified Issuer” under the Holding Foreign Companies Accountable Act.\n\n \n\nWe do not have any operations or subsidiaries organized in, or with a principal office in, a foreign jurisdiction that prevents the PCAOB from conducting inspections or investigations of registered public accounting firms.\n\n \n\n \n\n25\n\n*Table of Contents*\n\n \n\n**PART III**"}